News

 

 

Funding: New Awards

Thomas H. Davis, MD
Associate Professor
Cancer Control

  • Eli Lilly, Co.
    A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Konstantin H. Dragnev, MD
Associate Professor
Cancer Epidemiology and Chemoprevention

  • Pereqrine Pharmaceuticals, Inc.
    A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients with Previously Untreated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  • Eli Lilly, Co.
    A Randomized Phase 2 Study of LY2181308 in Combination with Docetaxel versus Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Were Previously Treated with First Line Chemotherapy

Camilo Fadul, MD
Professor
Immunology and Cancer Immunotherapy

  • DMS Study
    Measurement of Regulatory T Cells in Glioblastoma Multiforme Specimens and Correlation of Outcome

Ryan J. Halter, PhD
Assistant Professor
Cancer Imaging and Radiobiology

  • PI/Dept Funding
    Surgical Margin Assessment During Radical Prostatectomy - a Deformation Study

Deborah Ornstein, MD
Assistant Professor
Molecular Therapeutics

  • CSL Behring
    A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Keith Paulsen, PhD  
Professor
Cancer Imaging and Radiobiology

  • NCI: American College of Radiology Imaging Network
    Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI)

Gary Schwartz, MD
Associate Professor
Molecular Therapeutics

  • DMS
    PBX1 Expression and Endocrine Resistance in Subjects with Breast Cancer